Vira Shield 4+VL5 HBThis page contains information on Vira Shield 4+VL5 HB for veterinary use.
The information provided typically includes the following:
- Vira Shield 4+VL5 HB Indications
- Warnings and cautions for Vira Shield 4+VL5 HB
- Direction and dosage information for Vira Shield 4+VL5 HB
Vira Shield 4+VL5 HBThis treatment applies to the following species:
Bovine Rhinotracheitis-Virus Diarrhea Vaccine
Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
For Use In Animals Only
Vira Shield 4+VL5 HB Indications
For use in healthy breeding cattle, including pregnant cows and heifers, as an aid in the prevention of disease caused by infectious bovine rhinotracheitis (IBR) and bovine virus diarrhea (BVD Type 1 and BVD Type 2) viruses and Campylobacter fetus, Leptospira canicola, grippotyphosa, hardjo-bovis, icterohaemorrhagiae, and pomona. For use in calves vaccinated at four weeks of age, or older, as an aid in the prevention of hardjo-bovis kidney colonization, and as an aid in preventing urinary shedding and reproductive tract infection for 12 months. Produced from non-cytopathic (BVD Type 1 and BVD Type 2) and cytopathic (BVD Type 1) isolates. Vaccinated animals subsequently exposed to L. borgpetersenii serovar hardjo (type hardjo-bovis) have been shown to clear renal infections within 8 weeks of exposure.
ADJUVANT: Xtend™ SP.
Directions For Use
Shake well before using. Administer 5 mL subcutaneously 2-4 weeks prior to breeding. In accordance with Beef Quality Assurance guidelines, this product should be administered subcutaneously (under the skin) in the neck. Revaccinate in 4-5 weeks. Revaccinate annually or as recommended by your veterinarian.
PrecautionsStore out of direct sunlight at 2°-7°C (35°-45°F). DO NOT FREEZE. Use entire contents when first opened. Do not vaccinate within 60 days prior to slaughter. Transient swelling may occur at the site of injection. Milk reduction and transient depression may be observed in lactating dairy cows for 3-6 days following vaccination. Anaphylactic reactions may occur. Symptomatic treatment: Epinephrine. Contains amphotericin B, gentamicin, and thimerosal as preservatives.
U.S. Vet. License No. 196; Elanco US, Inc., Larchwood, IA 51241 USA; Elanco, Vira Shield, Xtend and the diagonal bar are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.
Distributed by ELANCO ANIMAL HEALTH
2500 INNOVATION WAY, GREENFIELD, IN, 46140
|Small Animal Product Customer Service:||888-545-5973|
|Every effort has been made to ensure the accuracy of the Vira Shield 4+VL5 HB information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-08-31